The ONLY ready-to-administar bag of Levetiracetam in Sodium Chloride Injection

Premixed bag targeted specifically for hospital use

Single-use 100-mL bags available in the following dosage forms and strengths:

  • Levetiracetam in 0.82% sodium chloride injection (500 mg/100 mL)
  • Levetiracetam in 0.75% sodium chloride injection (1000 mg/100 mL)
  • Levetiracetam in 0.54% sodium chloride injection (1500 mg/100 mL)


  • Premixed and ready to administer; no dilution required


  • Administered as a 15-minute IV infusion


  • Prelabeled, color-coded doses available in 3 strengths


  • Single-use, 100-mL dual port bag

    Dosing Instructions

    • Starting dose: 1000 mg/day, given as 500 mg twice daily
    • Dose increase: Every 2 weeks by 1000 mg/day as needed and tolerated to the recommended dose of 3000 mg/day*
    • For adult patients with impaired renal function, dosing must be individualized according to patient's renal function status. Please see full Prescribing Information for additional information
    • Patients must be advised to notify their physician if they are pregnant prior to therapy

    Storage Instructions

    • Store at 20°C to 25°C (68°F to 77°F)
    • Physically compatible and chemically stable for at least 24 hours when mixed with lorazepam, diazepam, and valproate sodium and stored at controlled room temperature 15°C to 30°C (59°F to 86°F)
    • Shelf life is 24 months.

    Indications and Important Safety Information

    Levetiracetam in Sodium Chloride Injection is an antiepileptic drug indicated as adjunctive therapy when oral administration is temporarily not feasible in adults (16 years and older) with: partial onset seizures; myoclonic seizures in patients with juvenile myoclonic epilepsy; primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy.

    Antiepileptic drugs (AEDs) increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Levetiracetam in Sodium Chloride Injection causes neuropsychiatric reactions including somnolence and fatigue, muscle coordination difficulties and behavioral abnormalities as well as hematological abnormalities. The most common adverse reactions observed with Levetiracetam were somnolence, weakness, infection and dizziness. Important behavioral adverse reactions include hallucinations, delusions, and non-psychotic mood disorders including suicide ideation, aggression, anger, apathy, conduct disorder, irritability, depression, nervousness, anxiety and emotional lability.

    Dosing must be individualized according to seizure type, patient's renal function status and therapy objective. Based on animal data, Levetiracetam may cause fetal harm and therefore should be used during pregnancy after consideration of the potential benefit-risk ratio. Levetiracetam should be gradually withdrawn to minimize the potential of increased seizure frequency.

    Click here for full Prescribing Information.

    * Please refer to the full Prescribing Information regarding the following:

    † There are no data to support the physical compatibility of Levetiracetam Injection with antiepileptic drugs that are not listed above.

    ©2015 Mylan Institutional. All rights reserved. The Mylan logo is a registered trademark of Mylan Inc.